Adamas Pharmaceuticals Inc (ADMS) - Financial and Strategic SWOT Analysis Review
Adamas Pharmaceuticals Inc (ADMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Adamas Pharmaceuticals Inc (Adamas Pharmaceuticals) discovers, develops and markets therapeutics for treatment of neurological diseases. The company's Gocovri is an amantadine extended-release capsule for the treatment for dyskinesia in patients with Parkinson’s disease. Gocovri is a high-dose, once-daily indication designed to deliver high level of amantadine in the morning and throughout the day when dyskinesia occurs. It also offers Namenda XR and Namzaric capsules for the treatment of moderate to severe Alzheimer’s dementia disease under an exclusive license agreement with Allergan. The company is investigating ADS-5102 in Phase III clinical trials for the treatment of walking impairment in patients with multiple sclerosis, and ADS-4101 in Phase III clinical trials for the treatment of partial onset seizures in patients with epilepsy. The company markets its products to distributors and specialty pharmacies through its sales force of neurology specialist and in collaboration with partners. Adamas Pharmaceuticals is headquartered in Emeryville, California, the US.
Adamas Pharmaceuticals Inc Key Recent Developments
Sep 13,2021: Adamas Pharmaceuticals and Westwood & Wilshire team up to hire Senior Director, Commercial Quality Assurance
Jun 23,2021: Adamas to Present at Upcoming SVB Leerink CNS Forum
Jun 08,2021: Adamas Pharmaceuticals announces board changes
May 10,2021: Adamas Reports First Quarter 2021 Financial Results
Apr 29,2021: Adamas to Present at Upcoming BofA Conference
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Adamas Pharmaceuticals Inc (Adamas Pharmaceuticals) discovers, develops and markets therapeutics for treatment of neurological diseases. The company's Gocovri is an amantadine extended-release capsule for the treatment for dyskinesia in patients with Parkinson’s disease. Gocovri is a high-dose, once-daily indication designed to deliver high level of amantadine in the morning and throughout the day when dyskinesia occurs. It also offers Namenda XR and Namzaric capsules for the treatment of moderate to severe Alzheimer’s dementia disease under an exclusive license agreement with Allergan. The company is investigating ADS-5102 in Phase III clinical trials for the treatment of walking impairment in patients with multiple sclerosis, and ADS-4101 in Phase III clinical trials for the treatment of partial onset seizures in patients with epilepsy. The company markets its products to distributors and specialty pharmacies through its sales force of neurology specialist and in collaboration with partners. Adamas Pharmaceuticals is headquartered in Emeryville, California, the US.
Adamas Pharmaceuticals Inc Key Recent Developments
Sep 13,2021: Adamas Pharmaceuticals and Westwood & Wilshire team up to hire Senior Director, Commercial Quality Assurance
Jun 23,2021: Adamas to Present at Upcoming SVB Leerink CNS Forum
Jun 08,2021: Adamas Pharmaceuticals announces board changes
May 10,2021: Adamas Reports First Quarter 2021 Financial Results
Apr 29,2021: Adamas to Present at Upcoming BofA Conference
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Adamas Pharmaceuticals Inc - Key Facts
Adamas Pharmaceuticals Inc - Key Employees
Adamas Pharmaceuticals Inc - Key Employee Biographies
Adamas Pharmaceuticals Inc - Major Products and Services
Adamas Pharmaceuticals Inc - History
Adamas Pharmaceuticals Inc - Company Statement
Adamas Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Adamas Pharmaceuticals Inc - Business Description
Business Segment: Product Sales
Performance
Business Segment: Royalty Revenue
Performance
R&D Overview
Adamas Pharmaceuticals Inc - Corporate Strategy
Adamas Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Adamas Pharmaceuticals Inc - Strengths
Adamas Pharmaceuticals Inc - Weaknesses
Adamas Pharmaceuticals Inc - Opportunities
Adamas Pharmaceuticals Inc - Threats
Adamas Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Adamas Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sep 13, 2021: Adamas Pharmaceuticals and Westwood & Wilshire team up to hire Senior Director, Commercial Quality Assurance
Jun 23, 2021: Adamas to Present at Upcoming SVB Leerink CNS Forum
Jun 08, 2021: Adamas Pharmaceuticals announces board changes
May 10, 2021: Adamas Reports First Quarter 2021 Financial Results
Apr 29, 2021: Adamas to Present at Upcoming BofA Conference
Apr 15, 2021: Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting
Apr 07, 2021: Adamas to Present at Upcoming Needham Conference
Feb 23, 2021: Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 17, 2021: Adamas to Present at Upcoming Healthcare Conferences
Feb 10, 2021: Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Adamas Pharmaceuticals Inc - Key Facts
Adamas Pharmaceuticals Inc - Key Employees
Adamas Pharmaceuticals Inc - Key Employee Biographies
Adamas Pharmaceuticals Inc - Major Products and Services
Adamas Pharmaceuticals Inc - History
Adamas Pharmaceuticals Inc - Company Statement
Adamas Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Adamas Pharmaceuticals Inc - Business Description
Business Segment: Product Sales
Performance
Business Segment: Royalty Revenue
Performance
R&D Overview
Adamas Pharmaceuticals Inc - Corporate Strategy
Adamas Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Adamas Pharmaceuticals Inc - Strengths
Adamas Pharmaceuticals Inc - Weaknesses
Adamas Pharmaceuticals Inc - Opportunities
Adamas Pharmaceuticals Inc - Threats
Adamas Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Adamas Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sep 13, 2021: Adamas Pharmaceuticals and Westwood & Wilshire team up to hire Senior Director, Commercial Quality Assurance
Jun 23, 2021: Adamas to Present at Upcoming SVB Leerink CNS Forum
Jun 08, 2021: Adamas Pharmaceuticals announces board changes
May 10, 2021: Adamas Reports First Quarter 2021 Financial Results
Apr 29, 2021: Adamas to Present at Upcoming BofA Conference
Apr 15, 2021: Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting
Apr 07, 2021: Adamas to Present at Upcoming Needham Conference
Feb 23, 2021: Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 17, 2021: Adamas to Present at Upcoming Healthcare Conferences
Feb 10, 2021: Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Adamas Pharmaceuticals Inc, Key Facts
Adamas Pharmaceuticals Inc, Key Employees
Adamas Pharmaceuticals Inc, Key Employee Biographies
Adamas Pharmaceuticals Inc, Major Products and Services
Adamas Pharmaceuticals Inc, History
Adamas Pharmaceuticals Inc, Subsidiaries
Adamas Pharmaceuticals Inc, Key Competitors
Adamas Pharmaceuticals Inc, Ratios based on current share price
Adamas Pharmaceuticals Inc, Annual Ratios
Adamas Pharmaceuticals Inc, Annual Ratios (Cont...1)
Adamas Pharmaceuticals Inc, Annual Ratios (Cont...2)
Adamas Pharmaceuticals Inc, Interim Ratios
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Adamas Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Adamas Pharmaceuticals Inc, Key Facts
Adamas Pharmaceuticals Inc, Key Employees
Adamas Pharmaceuticals Inc, Key Employee Biographies
Adamas Pharmaceuticals Inc, Major Products and Services
Adamas Pharmaceuticals Inc, History
Adamas Pharmaceuticals Inc, Subsidiaries
Adamas Pharmaceuticals Inc, Key Competitors
Adamas Pharmaceuticals Inc, Ratios based on current share price
Adamas Pharmaceuticals Inc, Annual Ratios
Adamas Pharmaceuticals Inc, Annual Ratios (Cont...1)
Adamas Pharmaceuticals Inc, Annual Ratios (Cont...2)
Adamas Pharmaceuticals Inc, Interim Ratios
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Adamas Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Adamas Pharmaceuticals Inc, Performance Chart (2016 - 2020)
Adamas Pharmaceuticals Inc, Ratio Charts
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Adamas Pharmaceuticals Inc, Performance Chart (2016 - 2020)
Adamas Pharmaceuticals Inc, Ratio Charts
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021